These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38375710)

  • 1. The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.
    Mi YJ; Zhang Z; Jin SL; Yan HM; Yang XM; Zhao J; Liu RX; Wu Y
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1052-1059. PubMed ID: 38375710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
    Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
    Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
    J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on the diagnostic value of transient elastography, APRI and FIB-4 for liver fibrosis in children with non-alcoholic fatty liver disease].
    He SL; Li SJ; Liu M; Ouyang WX; Chen WJ; Zheng X; Jiang T; Tan YF; Kang Z; Qin XM; Yu Y
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):81-86. PubMed ID: 35152674
    [No Abstract]   [Full Text] [Related]  

  • 6. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
    Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
    JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
    Zhang F; Han Y; Wu Y; Bao Z; Zheng G; Liu J; Li W
    Ann Med; 2024 Dec; 56(1):2409342. PubMed ID: 39348274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
    Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
    Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
    Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
    Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
    Amernia B; Moosavy SH; Banookh F; Zoghi G
    BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study.
    Kong W; Tang Y; Liu L; Zhang G; Liu Y; Liu J
    Ultrasound Med Biol; 2022 Dec; 48(12):2442-2448. PubMed ID: 36096895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of attenuation coefficient in the assessment of hepatic involvement in children and adolescents with Wilson's disease.
    Wang J; Wang J; Wang H; Li B; Wang Y; Sun L; Wu X
    BMC Med Imaging; 2023 Feb; 23(1):24. PubMed ID: 36739392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease.
    Tada T; Saibara T; Ono M; Takahashi H; Eguchi Y; Hyogo H; Kawanaka M; Kumada T; Toyoda H; Yasuda S; Nakajima A; Yoneda M; Tanaka S; Shimada K; Hoshino H; Aishima S; Kage M; Sumida Y
    Eur J Gastroenterol Hepatol; 2021 Nov; 33(11):1451-1458. PubMed ID: 34334708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.
    Liu XL; Pan Q; Zhang RN; Shen F; Yan SY; Sun C; Xu ZJ; Chen YW; Fan JG
    World J Gastroenterol; 2016 Nov; 22(44):9844-9852. PubMed ID: 27956809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
    Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
    Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.